{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/305499313"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "The $7.5 million increase is attributable to start-up activities for the Phase 3 trial (MATISSE) in small cell lung cancer (SCLC) that was initiated during the second quarter, expanded development and manufacturing activities supporting the Company's palifosfamide and synthetic biology therapeutics program, and severance and other costs related to the termination of certain employees announced in" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "ziopharm.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/356843920"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/305499313" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/152470215"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/305499313"] } } }
